Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EURO-EWING 99
ISRCTN61438620Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Feb 2001
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of vincristine, actinomycin D, ifosfamide, cyclophosphamide, busulfan and 1 more in Ewing sarcoma (6 arms), sponsored by University of Birmingham. Primary endpoints: Event-free survival and Overall survival. Started Feb 2001; status: completed.
02
Drugs
vincristineactinomycin Difosfamidecyclophosphamidebusulfan
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on ISRCTN61438620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61438620.